Thirty two HER2+ gastric cancer patients (IHC 3+ or IHC 2+/FISH+) received fluoropyrimidine-, platinum- and Trastuzumab-containing regimens as first-line therapy and irinotecan or taxanes with or without Trastuzumab as second-line therapy. Here, ERBB2 is linked to gastric cancer.